Dysport (TM), a new type of botulinum toxin type A, received U.S. FDA approval yesterday for the temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years of age.
An April 2009 article in the Archives of Facial Plastic Surgery, "Long-term Safety and Efficacy of a New Botulinum Toxin Type A in Treating Glabellar Lines", showed that injections with this new botulinum toxin appears to be well tolerated and may help to improve the appearance of moderate to severe forehead lines with no evidence of diminishing treatment response over 13 months.
"The onset of effect was seen as soon as 24 hours and at a median [midpoint] of three days during all cycles," the authors wrote. By day seven of each treatment cycle, 93 percent to 95 percent of patients reported a response to treatment, and between 80 percent and 91 percent had a response by day 30 based on the investigators' assessments
This new botulinum toxin type A has been used to treat neurological disorders outside the United States for more than 15 years and is approved to treat wrinkles in 23 countries. The product will be marketed for cosmetic use in the U.S. by Medicis under the name Dysport(TM).